Glucox Biotech AB
Glucox Biotech AB is a privately owned Stockholm based Swedish research company. On the basis of a favourable patent position, extensive experience in the development of medicines for metabolic diseases, and in collaboration with academic researchers and contract research organisations Glucox Biotech develops clinically applicable therapeutics for treatment of type 2 diabetes; hyperglycaemia, insulin resistance and resulting complications.
Glucox Biotech also explores new ideas for the prevention of cellular damage in ischemic stroke and heart infarction.
Erik Walum, PhD. CEO.
Erik Walum is a former professor of Neurotoxicology at Stockholm University and has served as Head of Molecular Biology and Genomics at Pharmacia and Head of Obesity Pharmacology at Biovitrum.
Per Wikström, PhD and founder of Glucox Biotech.
Per Wikström has many years of research experience in the pharmaceutical industry from Immunex in Seattle, Pharmacia and Pfizer, mainly in the field of metabolic disorders and projects related to insulin resistance.
Board of Directors
In addition Erik Walum and Per Wikström, the Company Managers, the Board of Directors includs Björn Sundeby, a major investor and share holder i Glucox Biotech AB.